Company reports robust sales of COVID-19 tests and net income per common share of $0.43

Salt Lake City, Utah – August 13, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the filing of its operating results for the 3 month period ending June 30, 2020 on SEC Form 10-Q, and provided updates on Company developments.

Q2 2020 Highlights:

  • Company continues COVID-19 test sales and reports $24.04 million of revenue in Q2;
  • Net profit of $12.6 million in quarter and net income per common share of $0.43;
  • Stockholders’ equity increased to $33.4 million compared to $1.7 million at the beginning of the year.
  • Gross margins of 70% on sales of Logix Smart™ COVID-19 test kits;
  • CoSara Diagnostics, Company’s India joint venture, receives authorization from CDSCO in India to manufacture and sell COVID-19 tests and records profit for the 2nd Quarter and YTD;
  • Received FDA Emergency Use Authorization for COVID-19 test kit on April 3, 2020;
  • Cash on hand was $18.6 million as of June 30, 2020, an increase of $17.7 million over 12/31/2019;
  • Company is included in the Russell 2000® and Russell 3000® Index, widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

Q3 2020 Mid-Quarter Highlights:

  • Company records COVID-19 test and equipment sales orders approaching $50 million YTD, including joint venture sales in India, through mid-third quarter (unaudited);
  • Receives purchase orders from public and private organizations in nearly 50 countries and over 25 states in the U.S. YTD;
  • Company nears completion of principal design work and verification for Flu A, Flu B, and COVID-19 multiplex panel with anticipated deployment during Q3;
  • Company announced that its partner Clinical Reference Lab has received FDA Emergency Use Authorization for CRL Rapid Response™, a saliva-based COVID-19 test that can be self-administered at home, work or any other setting and then tested using Co-Diagnostics’ Logix Smart COVID-19 tests based on patented CoPrimer™ technology.

“In the last 4 months since Co-Diagnostics received emergency use authorization from the FDA, the Company has successfully grown our internationally recognized business and brand. With clients in over 50 countries, 25 U.S. states, and validations of test accuracy from regulatory bodies of numerous countries around the world, Co-Diagnostics has established a distribution platform that we believe will continue to support sales and profitability as our tests have gained widespread acceptance in the market. We have created a test menu and established the production capacity to meet demand for tests as the nations of the world continue to battle the pandemic, and believe these efforts will continue to bolster the Company’s durability in the months and years to come,” said Dwight Egan, Chief Executive Officer.

The Company will host an earnings call at 4:30 pm EDT today. Participants can register for access to the webcast here. The call will be recorded and later made available on the Company’s website.

About Emergency Use Authorization:

The Co-Diagnostics SARS-CoV-2 Test has been made available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service’s (HHS’s) declaration that circumstances exist to justify the use of in vitro diagnostics (IVDs) under EUA for the detection and/or diagnosis of COVID-19. An IVD made available under an EUA has not undergone the same type of review as an FDA cleared IVD. However, based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective in the detection of COVID-19. The EUAs for these tests are in effect for the duration of the COVID-19 emergency, unless terminated or revoked (after which the tests may no longer be used). An FDA cleared IVD should be used instead of an IVD under EUA, when applicable and available.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.  





June 30, 2020 December 31, 2019
Current Assets
Cash and cash equivalents $ 18,550,437 $ 893,138
Accounts receivables, net 5,349,876 131,382
Inventory 10,110,786 197,168
Prepaid expenses 521,180 362,566
Total current assets 34,532,279 1,584,254
Other Assets
Property and equipment, net 473,376 196,832
Investment in joint venture 1,416,480 434,240
Total other assets 1,889,856 631,072
Total assets $ 36,422,135 $ 2,215,326
Current Liabilities
Accounts payable $ 1,127,709 $ 5,959
Accrued expenses 691,385 200,788
Accrued expenses (related party) 120,000 120,000
Deferred revenue 1,045,548 1,323
Total current liabilities 2,984,642 328,070
Long-term Liabilities, net of current portion
Accrued expenses-long-term (related party) 80,000 150,000
Total long-term liabilities, net of current portion 80,000 150,000
Total liabilities 3,064,642 478,070
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively 26
Common stock, $0.001 par value, 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding, as of June 30, 2020 and December 31, 2019, respectively. 27,991 17,343
Additional paid-in capital 46,726,869 26,687,701
Accumulated deficit (13,397,367 ) (24,967,814 )
Total stockholders’ equity 33,357,493 1,737,256
Total liabilities and stockholders’ equity $ 36,422,135 $ 2,215,326





For the Three Months
Ended June 30,
For the Six Months
Ended June 30,
2020 2019 2020 2019
Net revenue $ 24,040,274 $ 61,574 $ 25,588,802 $ 64,974
Cost of revenue 8,344,674 38,809 8,826,414 39,261
Gross profit 15,695,600 22,765 16,762,388 25,713
Operating expenses:
Sales and marketing 390,191 252,076 658,674 508,179
Administrative and general 2,191,034 807,769 3,650,518 1,448,132
Research and development 750,249 312,590 1,150,271 659,896
Depreciation and amortization 25,218 16,094 45,966 29,762
Total operating expenses 3,356,692 1,388,529 5,505,429 2,645,969
Income (loss) from operations 12,338,908 (1,365,764 ) 11,256,959 (2,620,256 )
Other expense:
Interest income 38,173 19,640 45,748 20,048
Interest expense (106,427 )
Gain on disposition of assets 850
Gain (loss) on equity method investment in joint venture 258,559 1,728 267,740 (7,000 )
Total other expense 296,732 21,368 313,488 (92,529 )
Income (loss) before income taxes 12,635,640 (1,344,396 ) 11,570,447 (2,712,785 )
Provision for income taxes
Net income (loss) $ 12,635,640 $ (1,344,396 ) $ 11,570,447 $ (2,712,785 )
Basic income (loss) per common share $ 0.46 $ (0.08 ) $ 0.42 $ (0.16 )
Diluted income (loss) per common share $ 0.43 $   (0.08 ) $ 0.40 $ (0.16 )
Weighted average common shares outstanding basic 27,582,229 17,017,964 27,605,137 16,544,926
Weighted average common shares outstanding diluted 29,152,222 17,017,964 29,094,475 16,544,926

Company Contact:
Andrew Benson
Co-Diagnostics Investor Relations
Investor Relations Contact:
Keith Pinder
Landon Capital